Larimar Therapeutics, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
LRMR Company Description
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
LRMR Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view LRMR Smart Score
Score Breakdown
LRMR Company Description
Show More
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of LRMR by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by LRMR's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of LRMR in WallStreetBets Daily Discussion
LRMR News
Recent insights relating to LRMR
CNBC Recommendations
Recent picks made for LRMR stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in LRMR
Corporate Flights
Flights by private jets registered to LRMR
Our Analysis